Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. 2007

Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
Department of Medicinal Chemistry, Pfizer Global Research and Development, La Jolla, 10770 Science Center Dr., San Diego, CA 92121-1194, USA. min.teng@pfizer.com

Following our previous publication describing the biological profiles, we herein describe the structure-activity relationships of a core set of quinoxalines as the hGLP-1 receptor agonists. The most potent and efficacious compounds are 6,7-dichloroquinoxalines bearing an alkyl sulfonyl group at the C-2 position and a secondary alkyl amino group at the C-3 position. These findings serve as a valuable starting point for the discovery of more drug-like small molecule agonists for the hGLP-1 receptor.

UI MeSH Term Description Entries
D007202 Indicators and Reagents Substances used for the detection, identification, analysis, etc. of chemical, biological, or pathologic processes or conditions. Indicators are substances that change in physical appearance, e.g., color, at or approaching the endpoint of a chemical titration, e.g., on the passage between acidity and alkalinity. Reagents are substances used for the detection or determination of another substance by chemical or microscopical means, especially analysis. Types of reagents are precipitants, solvents, oxidizers, reducers, fluxes, and colorimetric reagents. (From Grant & Hackh's Chemical Dictionary, 5th ed, p301, p499) Indicator,Reagent,Reagents,Indicators,Reagents and Indicators
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067757 Glucagon-Like Peptide-1 Receptor A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS). GLP-1 Receptor,GLP-1R Receptor,GLP1R Protein,GLP1R Receptor,GLP 1 Receptor,GLP 1R Receptor,Glucagon Like Peptide 1 Receptor,Peptide-1 Receptor, Glucagon-Like,Protein, GLP1R,Receptor, GLP-1,Receptor, GLP-1R,Receptor, GLP1R,Receptor, Glucagon-Like Peptide-1
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D054873 Dipeptidyl-Peptidase IV Inhibitors Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. DPP-4 Inhibitor,DPP-4 Inhibitors,DPP-IV Inhibitor,DPP-IV Inhibitors,DPP4 Inhibitor,DPP4 Inhibitors,Dipeptidyl Peptidase 4 Inhibitor,Dipeptidyl-Peptidase 4 Inhibitor,Dipeptidyl-Peptidase IV Inhibitor,Gliptin,Gliptins,Dipeptidyl-Peptidase 4 Inhibitors,DPP 4 Inhibitor,DPP 4 Inhibitors,DPP IV Inhibitor,DPP IV Inhibitors,Dipeptidyl Peptidase 4 Inhibitors,Dipeptidyl Peptidase IV Inhibitor,Dipeptidyl Peptidase IV Inhibitors,Inhibitor, DPP-4,Inhibitor, DPP-IV,Inhibitor, DPP4,Inhibitor, Dipeptidyl-Peptidase 4,Inhibitor, Dipeptidyl-Peptidase IV
D018027 Receptors, Glucagon Cell surface receptors that bind glucagon with high affinity and trigger intracellular changes which influence the behavior of cells. Activation of glucagon receptors causes a variety of effects; the best understood is the initiation of a complex enzymatic cascade in the liver which ultimately increases the availability of glucose to body organs. Glucagon Receptors,Glucagon Receptor,Receptor, Glucagon

Related Publications

Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
October 2012, Bioorganic & medicinal chemistry letters,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
June 2021, Nature communications,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
August 2017, ChemistryOpen,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
January 2009, Protein and peptide letters,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
December 2012, Biomedical research (Tokyo, Japan),
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
June 2022, Journal of medicinal chemistry,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
December 2012, Molecular pharmacology,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
January 2012, Experimental diabetes research,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
September 2010, The Journal of pharmacology and experimental therapeutics,
Min Teng, and Michael D Johnson, and Christine Thomas, and Dan Kiel, and James N Lakis, and Tim Kercher, and Shelley Aytes, and Jarek Kostrowicki, and Dilip Bhumralkar, and Larry Truesdale, and John May, and Ulla Sidelman, and Janos T Kodra, and Anker Steen Jørgensen, and Preben Houlberg Olesen, and Johannes Cornelis de Jong, and Peter Madsen, and Carsten Behrens, and Ingrid Pettersson, and Lotte Bjerre Knudsen, and Jens J Holst, and Jesper Lau
December 2014, Scientific reports,
Copied contents to your clipboard!